Biocartis Group NV's total inventories for the quarter that ended in Jun. 2023 was €17.88 Mil. Biocartis Group NV's average total inventories from the quarter that ended in Dec. 2022 to the quarter that ended in Jun. 2023 was €18.39 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Biocartis Group NV's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was €-1.24.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Biocartis Group NV's Days Inventory for the
six
months ended in Jun. 2023 was 250.93.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Biocartis Group NV's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.73.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biocartis Group NV's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.62.
Biocartis Group NV (LTS:0R72) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Biocartis Group NV's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biocartis Group NV's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Biocartis Group NV Total Inventories Related Terms
Biocartis Group NV Total Inventories Historical Data
* Premium members only.
The historical data trend for Biocartis Group NV's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Biocartis Group NV (LTS:0R72) has a Total Inventories of €17.88 Mil as of Jun. 2023. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biocartis Group NV and its competitors.
Is Biocartis Group NV's Total Inventories too high?
Biocartis Group NV's current Total Inventories is €17.88 Mil. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's Total Inventories compare to TMO and DHR?
Biocartis Group NV's Total Inventories of €17.88 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biocartis Group NV and its competitors. Biocartis Group NV's current Total Inventories is €17.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current Total Inventories of €17.88 Mil. The current Total Inventories is €17.88 Mil. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current Total Inventories is €17.88 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score
Get the complete analysis for LTS:0R72
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R72 has been successfully added to your 
